Cholestyramine

Summary

Cholestyramine (CHEMBL1201625) is an approved unknown (ATC C10AC01); indicated across 15 conditions including nephrotic syndrome and hypothyroidism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: C10AC01
• Indications: 15 conditions
• Clinical trials: 24

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201625
Name	Cholestyramine
Type	Unknown
Max phase	4
ATC	C10AC01

Also known as: A-3384, A3384, Cholestyramine, Cholestyramine light, Cholybar, Colestiramina, Colestyramine, Colestyramine 20, Cuemid, Duolite ap143 resin, Locholest, Locholest light

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
nephrotic syndrome	4	MONDO:0005377	EFO:0004255
hypothyroidism	4	MONDO:0005420	EFO:0004705
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
myocardial infarction	3	MONDO:0005068	EFO:0000612
familial hypercholesterolemia	3	MONDO:0005439	EFO:0004911
myocardial ischemia	3	MONDO:0024644	EFO:1001375
Graves disease	3	MONDO:0005364	EFO:0004237
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
coronary artery disorder	3	MONDO:0005010	EFO:0001645
heart disorder	3	MONDO:0005267	EFO:0003777
hyperthyroidism	3	MONDO:0004425	EFO:0009189
smoldering plasma cell myeloma	2	MONDO:0005235	EFO:0003073
kidney disorder	1	MONDO:0005240	EFO:0003086

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
PHASE3	7
PHASE1	7
PHASE2	4
PHASE4	3
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01062269	PHASE4	COMPLETED	A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study
NCT01122108	PHASE4	COMPLETED	Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale
NCT02249897	PHASE4	COMPLETED	PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs
NCT06141473	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT00000463	PHASE3	COMPLETED	Post Coronary Artery Bypass Graft (CABG) Study
NCT00000488	PHASE3	COMPLETED	Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)
NCT00000594	PHASE3	COMPLETED	NHLBI Type II Coronary Intervention Study
NCT01863888	PHASE3	COMPLETED	Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
NCT03510715	PHASE3	COMPLETED	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
NCT03510884	PHASE3	COMPLETED	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT05014646	PHASE2	ACTIVE_NOT_RECRUITING	Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
NCT00000461	PHASE2	COMPLETED	Harvard Atherosclerosis Reversibility Project (HARP)
NCT02078856	PHASE2	COMPLETED	Double-blind, Randomised Study of A3384 in BAM/BAD
NCT02890992	PHASE2	COMPLETED	An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT05443425	PHASE1	RECRUITING	Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
NCT06454383	PHASE1	RECRUITING	Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
NCT01239459	PHASE1	COMPLETED	Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment
NCT02046629	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
NCT02963077	PHASE1	COMPLETED	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
NCT04335526	PHASE1	COMPLETED	A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles
NCT05894928	PHASE1	COMPLETED	A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
NCT05966727	Not specified	RECRUITING	Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
NCT00677469	Not specified	COMPLETED	Low Doses of Cholestyramine in the Treatment of Hyperthyroidism
NCT02942602	Not specified	COMPLETED	Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).